TriSalus Life Sciences Stock (NASDAQ:TLSI)

Revenue Ownership Financials Chart Transcripts

Previous Close

$4.26

52W Range

$3.42 - $7.95

50D Avg

$5.28

200D Avg

$5.18

Market Cap

$157.71M

Avg Vol (3M)

$188.34K

Beta

0.44

Div Yield

TLSI Company Profile

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

110

IPO Date

Feb 08, 2021

Website

TLSI Performance

TLSI Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$45.15M	$29.43M	$18.51M
Operating Income	$-26.95M	$-36.16M	$-54.48M
Net Income	$-69.69M	$-33.23M	$-59.36M
EBITDA	$-26.95M	$-36.16M	$-58.65M
Basic EPS	$-1.84	$-1.25	$-2.23
Diluted EPS	$-1.84	$-1.25	$-2.23

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 05, 26 | 4:30 PM

Q3 25Nov 13, 25 | 4:30 PM

Q2 25Aug 12, 25 | 4:30 AM

Peer Comparison

Ticker	Company
STIM	Neuronetics, Inc.
AVR	Anteris Technologies Global Corp.
LNSR	LENSAR, Inc.
MXCT	MaxCyte, Inc.
PRE	Prenetics Global Limited
NNOX	Nano-X Imaging Ltd.
OWLT	Owlet, Inc.
CATX	Perspective Therapeutics, Inc.
PROF	Profound Medical Corp.